Rani Therapeutics Holdings, Inc. (RANI)
0.854
+0.01
(+1.67%)
USD |
NASDAQ |
Aug 31, 15:09
Rani Therapeutics Holdings Profit Margin (Quarterly) : -493.0% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -493.0% |
| March 31, 2026 | -469.3% |
| December 31, 2025 | -621.1% |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | -7.41K% |
| December 31, 2024 | -1.53K% |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 |
| Date | Value |
|---|---|
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | -279.7% |
| March 31, 2021 | -740.5% |
| September 30, 2020 | -2.67K% |
| June 30, 2020 | -4.52K% |
| March 31, 2020 | -6.45K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -3.01K% |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 67.84% |
| Fulcrum Therapeutics, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -160.8% |
| Return on Assets | -84.24% |
| Return on Invested Capital | -107.9% |
| Gross Profit Margin (Quarterly) | 88.29% |
| Operating Margin (Quarterly) | -516.9% |
| Return on Net Operating Assets | -552.2% |